BIOMAT Database Logo BIOMAT Database Logo

Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. 1996

J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

The (S)- and (R)-enantiomers of 9-(2-phosphonylmethoxypropyl) derivatives of adenine (PMPA) and 2,6-diaminopurine (PMPDAP) were evaluated for their inhibitory effect on HIV replication in several human cell systems, including natural peripheral blood lymphocytes (PBL) and freshly isolated monocyte/macrophages (M/M). The (R)-enantiomers of PMPDAP and PMPA were approximately 10-to-100-fold more effective against HIV than their (S)-enantiomeric counterparts. The antiviral efficacy of (R)-PMPA was comparable to that of the prototype acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine (PMEA). The most potent and selective HIV inhibitor was (R)-PMPDAP. Its 50% effective concentration ranged from 0.01 microM for HIV-1/Ba-L in M/M to 1-2.8 microM for HIV-1/IIIB and HIV-1/HE in C8166, CEM, Molt/4, MT-4 and PBL cells. Both (R)-PMPA and (R)-PMPDAP were not toxic to the host cells at 300 microM.

UI MeSH Term Description Entries
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012999 Soman An organophosphorus compound that inhibits cholinesterase. It causes seizures and has been used as a chemical warfare agent. Pinacolyl Methylphosphonofluoridate,Methylphosphonofluoridate, Pinacolyl
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications

Related Publications

J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
(R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection.
March 1995, Antimicrobial agents and chemotherapy,
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Antiviral treatment of feline immunodeficiency virus-infected cats with (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine.
February 2015, Journal of feline medicine and surgery,
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Efficacy and adverse effects of (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine in feline immunodeficiency virus-infected cats.
January 2012, Journal of veterinary internal medicine,
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Clinical efficacy of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) in the treatment of feline immunodeficiency virus-infected cats.
February 2012, Journal of feline medicine and surgery,
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus.
February 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Potent and selective activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside, 3'-fluoro-2,6-diaminopurine-2',3'-dideoxyriboside, and 3'-fluoro-2',3'-dideoxyguanosine against human immunodeficiency virus.
March 1988, Molecular pharmacology,
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine.
August 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
November 1995, Science (New York, N.Y.),
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate.
October 2006, Virology,
J Balzarini, and S Aquaro, and C F Perno, and M Witvrouw, and A Holý, and E De Clercq
Electronic relaxation mechanism of 9-methyl-2,6-diaminopurine and 2,6-diaminopurine-2'-deoxyribose in solution.
January 2024, Photochemistry and photobiology,
Copied contents to your clipboard!